- 作者:Anish Bhatt ; Anand Rohatgi
- 关键词:HDL ; Cholesterol efflux ; Reverse cholesterol transport ; Atherosclerosis ; Cardiovascular
- 刊名:Current Atherosclerosis Reports
- 出版年:2016
- 出版时间:January 2016
- 年:2016
- 卷:18
- 期:1
- 全文大小:449 KB
- 参考文献:1.Stone NJ et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–S45.CrossRef PubMed
2.Cholesterol Treatment Trialists, C et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90.CrossRef
3.Sabatine MS et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500–9.CrossRef PubMed
4.Robinson JG et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–99.CrossRef PubMed
5.Assmann G et al. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996;124 Suppl:S11–20.CrossRef PubMed
6.Barter P et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301–10.CrossRef PubMed
7.Emerging Risk Factors, C et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993–2000.CrossRef
8.Gordon T et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62(5):707–14.CrossRef PubMed
9.Prospective Studies Collaboration, Lewington S, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829–39.CrossRef
10.Sharrett AR et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104(10):1108–13.CrossRef PubMed
11.Turner RC et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316(7134):823–8.PubMedCentral CrossRef PubMed
12.Keene D et al. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ. 2014;349:g4379.PubMedCentral CrossRef PubMed
13.Group, H.T.C. et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–12.CrossRef
14.The AIM-HIGH Investigators et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67.CrossRef
15.Barter PJ et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109–22.CrossRef PubMed
16.•
Schwartz GG et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089–99. Dal-OUTCOMES was a r
andomized controlled trial studying the effects of CETP inhibition on recurrent cardiovascular events. Over 15,000 patients were r
andomized to dalcetrapib or placebo
and followed for a median of 31 months. Despite a significant increase in HDL-C in the dalcetrapib group, there was no significant reduction in recurrent cardiovascular events. This study emphasized that targeting HDL-C reduction may not reduce cardiovascular events.CrossRef PubMed
17.Terasaka N et al. High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting
efflux of 7-keto
cholesterol via ABCG1. Proc Natl Acad Sci U S A. 2007;104(38):15093–8.PubMedCentral CrossRef PubMed
18.Rosenson RS et al. Cholesterol
efflux and atheroprotection: advancing the concept of reverse
cholesterol transport. Circulation. 2012;125(15):1905–19.PubMedCentral CrossRef PubMed
19.Tall AR et al. HDL, ABC
transporters,
and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 2008;7(5):365–75.CrossRef PubMed
20.Rader DJ et al. The role of reverse
cholesterol transport in animals
and humans
and relationship to atherosclerosis. J Lipid Res. 2009;50(Suppl):S189–94.PubMedCentral PubMed
21.Out R et al. Combined deletion of macrophage ABCA1
and ABCG1 leads to massive lipid accumulation in tissue macrophages
and distinct atherosclerosis at relatively low plasma
cholesterol levels. Arterioscler Thromb Vasc Biol. 2008;28(2):258–64.CrossRef PubMed
22.Rohatgi A. High-density lipoprotein function measurement in human studies: focus on
cholesterol efflux capacity. Prog Cardiovasc Dis. 2015;58(1):32–40.CrossRef PubMed
23.Yvan-Charvet L et al. Combined deficiency of ABCA1
and ABCG1 promotes foam cell accumulation
and accelerates atherosclerosis in mice. J Clin Invest. 2007;117(12):3900–8.PubMedCentral PubMed
24.Khera AV et al. Cholesterol
efflux capacity, high-density lipoprotein function,
and atherosclerosis. N Engl J Med. 2011;364(2):127–35.PubMedCentral CrossRef PubMed
25.Bauer M et al. Carotid intima-media thickness as a biomarker of subclinical atherosclerosis. Swiss Med Wkly. 2012;142:w13705.PubMed
26.Taylor AJ et al. Progression of calcified coronary atherosclerosis: relationship to coronary risk factors
and carotid intima-media thickness. Atherosclerosis. 2008;197(1):339–45.CrossRef PubMed
27.Salahuddin T, Natarajan B, Playford MP, Joshi AA, Teague H, Masmoudi Y, et al. Cholesterol
efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis. Eur Heart J. 2015;36(39):2662–5.
28.Lim TK et al. Normal value of carotid intima-media thickness—a surrogate marker of atherosclerosis: quantitative assessment by B-mode carotid ultrasound. J Am Soc Echocardiogr. 2008;21(2):112–6.CrossRef PubMed
29.Ishikawa T et al. High-density lipoprotein
cholesterol efflux capacity as a relevant predictor of atherosclerotic coronary disease. Atherosclerosis. 2015;242(1):318–22.CrossRef PubMed
30.••
Li XM et al. Paradoxical association of enhanced
with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol. 2013;33(7):1696–705. This study prospectively followed 1150 patients with high cardiovascular risk after measuring baseline CEC. The highest tertile of CEC exhibited an increased risk of both incident nonfatal myocardial infarction
cardiovascular death. These results are in contrast with other observational studies.PubMedCentral CrossRef PubMed